醫生調查：醫生真正希望從 MSL 獲得什麼以及哪些方面可以改進

背景

隨著 MSL 在製定治療領域策略方面發揮的策略性和影響力日益凸顯，製藥公司必須了解醫療保健專業人員 (HCP) 在與 MSL 的互動中最希望獲得什麼，並衡量 MSL 滿足其需求的有效性。例如，自 COVID-19 疫情以來，混合互動模式增加，MSL 和 HCP 對此是否意見一致？

本報告對法國、德國、義大利、西班牙、英國和美國的 417 名醫生進行了調查，以了解他們對與 MSL 互動的感受以及如何改進。這些醫生來自五個專科：心臟病學、內分泌學、神經病學、腫瘤學和風濕病學。

關鍵問題解答

• 1. 整體而言，您對目前與製藥公司 MSL（注意：非銷售人員）的互動滿意度如何？
• 2. 您希望如何與藥廠 MSL（注意：非銷售人員）溝通？
• 3. 您認為 MSL 主動向您和您的診所提供的科學和產品資訊對您以及您的診所有何影響？
• 4. 您希望多久與藥廠 MSL（注意：非銷售人員）互動一次？
• 5. 您希望進行哪些改變，以最大程度地改善您與製藥公司 MSL（注意：非銷售人員）互動的體驗？

The backstory:

As the MSL role is increasingly recognised as more strategic and influential in shaping therapeutic area strategies, it is vital for pharmaceutical companies to understand what healthcare professionals (HCPs) want most from MSL interactions and to gauge how effectively MSLS are meeting their needs. For instance, are MSLs and HCPs on the same page when it comes to the hybrid engagement models that have increased since the COVID-19 pandemic?

The physician view:

FirstWord recently polled 417 doctors from France, Germany, Italy, Spain, the UK and US to gain an inside look at how they feel about their MSL interactions and how they could be improved. These physicians work across five specialties: cardiology, endocrinology, neurology, oncology and rheumatology.

Key Questions Answered:

• 1. How satisfied are you overall with your current interactions with medical science liaison (MSL) representatives from pharmaceutical companies? (note: not sales representatives)
• 2. How would you prefer to communicate with MSLs from pharmaceutical companies? (note: not sales representatives)
• 3. Typically, how useful is the unsolicited scientific and product information MSLs provide to you and your practice?
• 4. Please indicate how often you would like to interact with MSLs from pharmaceutical companies? (note: not sales representatives).
• 5. What one change would most improve your interaction experience with MSLs from pharmaceutical companies? (note: not sales representatives)

Methodology:

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.